Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Rectal Neoplasms 1Precancerous Conditions 1Hearing Loss 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Radiotherapy 3Cisplatin 2Cetuximab 2Bortezomib 2fludarabine 1aldesleukin 1Specimen Handling 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Esophagectomy 1Cyclophosphamide 1Chemoradiotherapy 1Biopsy 1Bevacizumab 1Atorvastatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Squamous Cell × Atorvastatin × Clear all
NCT04915183 2026-06-03

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡